🐦 推特Matthew Herper (STAT)Codex · 实盘不做把握 2/10
北京时间·🕒 发布 21:24:04时区推断·⟳ 抓取 21:24:28·⚡ 决策 07-30 21:25:34 +1m06s·88.9 天前
STAT记者预告直播Replimune黑色素瘤疗法FDA小组会
这条信号只是记者预告将直播FDA小组会流程，并未披露投票结果、监管新意见或公司新增经营事实。
📄 原文Matthew Herper (STAT)@matthewherper↗ 原文
"Hey Matt, what are you doing today?" Hey X, I'm glad you asked! Today @elaineywchen and I will be live-blogging the FD…
不做 Replimune（REPL.US）
只是FDA小组会直播预告，缺少新增监管结论、投票结果或可量化方向；盘前不做，等小组会实质结果由新信号研判。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-30 · 扩散 low · price-in 风险 medium ↗
关键理由
- 这条信号只是记者预告将直播FDA小组会流程，并未披露投票结果、监管新意见或公司新增经营事实。
主要风险
- 真正可交易的信息需等FDA小组会实质讨论、投票结果或公司/监管后续公告。
原文全文
展开原文 · 651 字
"Hey Matt, what are you doing today?"
Hey X, I'm glad you asked! Today @elaineywchen and I will be live-blogging the FDA panel on Replimune's experimental melanoma treatment.
The rejection of this treatment has been the center of controversy. But while it occurred under the Makary/Prasad FDA, @adamfeuerstein's reporting indicated it actually had to do with the objections of FDA staff -- something borne out by the briefing documents released earlier in the week.
We'll have a blow-by-blow of the proceedings, although based on the schedule we may not have much to say until later in the morning.
Tune in!
https://t.co/yp17hWIq7i via @statnews
Hey X, I'm glad you asked! Today @elaineywchen and I will be live-blogging the FDA panel on Replimune's experimental melanoma treatment.
The rejection of this treatment has been the center of controversy. But while it occurred under the Makary/Prasad FDA, @adamfeuerstein's reporting indicated it actually had to do with the objections of FDA staff -- something borne out by the briefing documents released earlier in the week.
We'll have a blow-by-blow of the proceedings, although based on the schedule we may not have much to say until later in the morning.
Tune in!
https://t.co/yp17hWIq7i via @statnews
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。